Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy on cognitive impairment and
functioning of several doses of PXT00864 (new fixed combination of acamprosate and baclofen
at low dose) in patients with mild Alzheimer Disease.